Ginkgo Bioworks Holdings
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -132.7% | -166.4% | -235.2% | -150.1% | -116.2% | -96.8% | -106.6% | -81.2% | -81.4% | -142.8% | -239.7% | -219.7% | -152.2% | |
| 38.0% | 36.9% | 33.9% | 30.8% | 19.3% | 35.7% | 31.8% | 31.8% | 36.5% | 40.9% | 65.7% | 61.1% | 47.3% | |
| 94.8% | 123.3% | 107.5% | 66.1% | 15.6% | 46.9% | 42.3% | 44.8% | 45.9% | 63.0% | 81.4% | 37.7% | 55.7% | |
| 380.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -3.3% | 121.0% | 0.8% | 10.5% | -110.1% | 5.0% | -23.9% | -45.8% | 35.5% | -70.6% | -72.8% | -65.2% | -33.2% | |
| 7.9% | 9.9% | 17.7% | 48.1% | 16.9% | 31.3% | 15.8% | 0.1% | 19.7% | 45.9% | 9.9% | 13.0% | 24.6% | |
| -6.1% | -134.3% | -31.9% | -47.8% | -11.5% | -29.8% | -411.2% | -128.8% | -187.5% | 284.8% | 118.8% | 55.0% | 50.5% | |
| – | 1.6% | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.1% | – | – | 0.1% | 0.2% | 0.0% | 0.0% | 26.6% | 58.3% | – | – | – | |
| -0.6% | – | – | – | -0.2% | -0.5% | -0.4% | -0.2% | -0.1% | -0.1% | -0.1% | 0.0% | -0.1% | |
| -0.6% | -1.8% | -2.2% | -0.4% | -0.5% | -0.5% | -0.4% | -0.2% | 25.6% | 24.4% | -0.1% | 81.8% | 30.9% | |
| -139.7% | -298.5% | -277.0% | -197.6% | -127.6% | -127.3% | -518.1% | -213.4% | -243.0% | 162.8% | -121.7% | -82.6% | -71.9% | |
| -140.6% | -176.3% | -252.9% | -198.2% | -133.2% | -128.0% | -122.4% | -81.2% | -81.4% | -188.7% | -249.7% | -232.6% | -170.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.